Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06907251
PHASE3
Dapagliflozin for Long COVID Syndrome
Sponsor: Ottawa Heart Institute Research Corporation
View on ClinicalTrials.gov
Summary
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
192
Start Date
2026-04-01
Completion Date
2029-06-30
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dapagliflozin (DAPA)
Dapagliflozin 10mg orally once a day for 12 months
DRUG
Placebo
Participants will receive a matching placebo taken once daily by mouth for 12 months.
Locations (1)
University of Ottawa Heart Institute
Ottawa, Ontario, Canada